Previous studies demonstrated that genetic and pharmacological inhibition of SIRT1 results in increased induction of p53-dependent apoptosis, both in somatic cancer cells and in cancer stem cells.3, 62 These findings make SIRT1 a promising target in cancer therapy. The gene discussed is TP53; the disease is cancer.